Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSD-101 in Relapsed or Refractory EBV-associated Hematological Malignancies
NCT07532746Phase 1Not yet recruiting
- Sponsor
- Kousai Bio
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous monocyte-derived DCs pulsed with EBV antigen in hematologic malignancy, sponsored by Kousai Bio. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events. Planned start May 2026; status: not yet recruiting.
02
Drugs
autologous monocyte-derived DCs pulsed with EBV antigen
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT07532746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07532746.